



Procter & Gamble Health announces results for the Fourth Quarter & Fiscal Year ended March 31, 2026

Sales up 20%, PAT up 55% for the quarter ended March 31, 2026

Sales up 16%, PAT up 30% for the Fiscal Year ended March 31, 2026 (vs comparable 12-months period in the last year)

Considering that the company, effective last year, changed its Financial Year from a July 1 – June 30 period to April 1 – March 31 period, the fiscal Year 2024-2025 of the Company covered a period of 9 months from July 1, 2024, to March 31, 2025. Therefore, the company performance has been indexed versus the comparable 12-months period in the last year (April 1, 2024, to March 31, 2025).

Mumbai, May 26, 2026: Procter & Gamble Health Ltd. (“the Company”) today announced its financial results for the fourth quarter and financial year ended March 31, 2026. During the quarter, the Company delivered sales of ₹365 crores, up 20% versus a year ago, driven by strong brand fundamentals and positive consumer response to new innovations. Profit After Tax (PAT) stood at ₹95 crores for the quarter, up 55% versus a year ago led by superior brand building activities and supported by strengthened supply chain and go-to-market capabilities.

With this, the company closed the 12-month Financial Year with reported sales of ₹1385 crores and PAT of ₹327 crores, up 16% and 30% respectively versus the comparable 12-month period last year (April 2024 - March 2025).

Considering that the company, effective last year, changed its Financial Year from a July 1 – June 30 period to a April 1 – March 31 period, the fiscal Year 2024-2025 of the Company covered a period of 9 months from July 1, 2024, to March 31, 2025. Therefore, the company performance has been indexed versus the comparable 12-months period in the last year (April 1, 2024, to March 31, 2025). The performance will not be comparable versus a 9-month past fiscal.

Milind Thatte, Managing Director, Procter & Gamble Health Limited, said, “We delivered a strong year with consistent top-line and bottom-line growth. We continued to invest across the value chain to address the evolving needs of our consumers and healthcare professionals. These include superior innovations that are backed by science to help our consumers live healthier and more vibrant lives, and consumer communication initiatives, as well as strengthened go-to-market and supply chain capabilities.

We are delivering sustainable, balanced growth and value creation for all our stakeholders, driven by our strategy that is centred on a focused portfolio of quality, trusted and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution and value), constructive disruption, productivity, and an agile accountable organization.”

The Company’s business continues to grow behind a strong suite of product innovations keeping the consumers at the centre. This includes the new **Livogen Iron Gummies** – a strawberry-flavoured, easy-to-consume, delightful format of iron supplementation. **Neurobion Nerve Pain Relief Cream** – a specialised topical solution designed to provide symptomatic relief from nerve-related pain, tingling and burning sensations in the hands and feet.

During the year, the Company continued to create a positive impact in the communities it serves through its Corporate Social Responsibility initiative – P&G Sehat. The initiative provides healthcare access and drives healthcare awareness in underserved communities across the country and has impacted over 15 lakh lives since its inception.

Procter & Gamble Health Limited

CIN: L99999MH1967PLC013726

Registered Office: Ground Floor and First Floor,

P&G Plaza, Cardinal Gracias Road, Chakala,

Andheri-E, Mumbai-400 099 | Tel: (91-22) 6866 9000

www.pghealthindia.com



The Board of Directors have recommended a final dividend of ₹ 45/- per Equity Share for the Financial Year ended March 31, 2026, subject to the approval of Shareholders of the company at the ensuing 59th Annual General Meeting. Considering the interim dividend of ₹160 per share paid on February 27, 2026, the total dividend payout for the fiscal will be ₹205 per share.

About Procter & Gamble Health Limited: Procter & Gamble Health Limited is one of India's largest vitamins, minerals, and supplements (VMS) companies manufacturing and marketing VMS products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Please visit www.pghealthindia.com for the latest news and information about Procter & Gamble Health Limited and its brands.

About Procter & Gamble: P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur®, Ariel®, Gillette®, Braun®, Head & Shoulders®, Olay®, Oral-B®, Pampers®, Pantene®, Herbal Essences®, Tide®, Vicks®, Old Spice® and Whisper®. P&G operates in approximately 70 countries worldwide.

CONTACTS

Media Contacts - Procter & Gamble Health Limited:

Vishesh Bohre | bohre.v@pg.com

Agency Contact – SPAG FINN Partners

Sarah Rajan | sarah.rajan@finnpartners.com

Desiree Crasto | desiree.crasto@finnpartners.com

Procter & Gamble Health Limited

CIN: L99999MH1967PLC013726

Registered Office: Ground Floor and First Floor,
P&G Plaza, Cardinal Gracias Road, Chakala,
Andheri-E, Mumbai-400 099 | Tel: (91-22) 6866 9000
www.pghealthindia.com